4D Molecular Therapeutics, Inc.

Informe acción NasdaqGS:FDMT

Capitalización de mercado: US$482.5m

4D Molecular Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de 4D Molecular Therapeutics es David Kirn , nombrado en Sep 2013, tiene una permanencia de 12.75 años. compensación anual total es $2.05M, compuesta por 32.5% salario y 67.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.17% de las acciones de la empresa, por valor de $15.30M. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 5.6 años, respectivamente.

Información clave

David Kirn

Chief Executive Officer (CEO)

US$2.1m

Compensación total

Porcentaje del salario del CEO32.53%
Permanencia del CEO12.8yrs
Participación del CEO3.2%
Permanencia media de la dirección1.6yrs
Promedio de permanencia en la Junta Directiva5.6yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • May 11

Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report

Investors in 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) had a good week, as its shares rose 7.4% to close at...
Seeking Alpha • Dec 19

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop

Summary 4D Molecular Therapeutics hinges on 4D-150 for wet AMD, targeting infrequent dosing versus current standards and a pivotal Phase 3 readout in 2027. The recent Otsuka partnership secures $85M upfront, cost sharing, and milestones, extending FDMT’s cash runway into 2028 and supporting global development. 4D-710's early cystic fibrosis data shows promise but lacks clear efficacy in gold-standard endpoints, leaving future prospects uncertain and market reaction muted. Despite multi-billion-dollar market opportunities, current data does not justify a bullish stance; financial risk remains material if pivotal results disappoint. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Summary 4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME. Despite market skepticism about gene therapy, 4DMT's solid science, regulatory clarity, and financial stability make it a compelling investment opportunity. Read the full article on Seeking Alpha
Artículo de análisis • Nov 24

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 04

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Summary 4D Molecular Therapeutics' lead candidate, 4D-150, aims to provide a one-time gene therapy for Wet-AMD, showing promising but mixed Phase 2 data. Despite setbacks, 4D-150's potential for less frequent dosing and robust safety profile make it an intriguing investment, especially given 4D's strong cash position. The competitive landscape is fierce, with rivals like AbbVie and Adverum, but 4D-150 could still achieve significant market share if approved. Market sell-off appears overdone; 4D's well-funded position and diverse pipeline offer a compelling contrarian bet for risk-tolerant investors. Read the full article on Seeking Alpha
Artículo de análisis • Aug 10

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jul 19

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Summary A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial initiation is expected in Q1 2025. Results from the phase 2 SPECTRA study, using the same gene therapy 4D-150 for the treatment of patients with diabetic macular edema, expected in Q4 of 2024. The global diabetic macular edema market is expected to reach $3.93 billion by 2029. 1E15 vg dose of 4D-710 cleared for dose expansion portion of phase 2 AEROW study; Updated interim data expected in mid-2025. Read the full article on Seeking Alpha
Seeking Alpha • Apr 29

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Summary 4D Molecular Therapeutics is a biotechnology company that develops genetic medicines using its Therapeutic Vector Evolution platform. The company's pipeline includes promising ophthalmology, pulmonology, and cardiology candidates, with Phase 3 progress for wet AMD and cystic fibrosis treatments. FDMT's platform allows for quickly creating custom viral vectors tailored to specific diseases, setting it apart from competitors. FDMT's recent public offering bolsters its position and extends its cash runway to 5.8 years, allowing time for research and clinical trials. I believe FDMT stock is a strong buy, driven by its innovative platform and a robust pipeline with a solid cash position. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Summary 4D Molecular Therapeutics' gene therapy, 4D-150, shows potential to reduce the treatment burden for patients with severe wet AMD. Interim findings from a Phase 2 trial demonstrate up to an 89% reduction in yearly anti-VEGF injections with 4D-150. FDMT plans to initiate a Phase 3 trial in wet AMD in Q1 2025, positioning 4D-150 as a promising candidate in the treatment landscape. Read the full article on Seeking Alpha
Seeking Alpha • Jan 25

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Summary Interim phase 1 data update using 4D-710 for the treatment of patients with Cystic Fibrosis expected in mid-2024. Program update on advancement of 4D-710 into pivotal study either alone or in combination with CFTR modular expected in Q1 of 2024. The global cystic fibrosis market is expected to reach $37.04 billion by 2030. The proprietary Therapeutic Vector Evolution platform has the ability to enhance transgene expression and allow for the ability to overcome limitations observed in prior AAV gene therapies. Read the full article on Seeking Alpha
Artículo de análisis • Nov 12

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) just released its quarterly report and things are looking bullish...
Artículo de análisis • Nov 08

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Kirn en comparación con los beneficios de 4D Molecular Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$161m

Dec 31 2025US$2mUS$667k

-US$140m

Sep 30 2025n/an/a

-US$209m

Jun 30 2025n/an/a

-US$196m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$1mUS$663k

-US$161m

Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$105m

Dec 31 2023US$10mUS$597k

-US$101m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$586k

-US$107m

Sep 30 2022n/an/a

-US$105m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$5mUS$570k

-US$71m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$702kUS$451k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$554kUS$430k

-US$49m

Compensación vs. Mercado: La compensación total ($USD2.05M) de David está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.57M).

Compensación vs. Ingresos: La compensación de David ha aumentado mientras la empresa no es rentable.

CEO

David Kirn (63 yo)

12.8yrs
Permanencia
US$2,051,343
Compensación

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc. He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013 and serve...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
John Milligan
Executive Chairman5.8yrsUS$255.00k0.19%
$ 923.0k
David Kirn
Co-Founder12.8yrsUS$2.05m3.17%
$ 15.3m
Kristian Humer
CFO and Principal Financial & Accounting Officerless than a yearUS$3.99msin datos
Fariborz Kamal
Chief Technical Advisorless than a yearUS$1.44m0.011%
$ 54.9k
Theresa Janke
Co-Founder & Chief of Staff13.4yrsUS$2.70msin datos
Julian Pei
Head of Investor Relations & Corporate Financeno datasin datossin datos
Katy Barglow
Chief Technical Officerless than a yearsin datossin datos
Scott Bizily
Chief Legal Officer & Corporate Secretary4.8yrssin datos0.0069%
$ 33.2k
An Song
Chief Translational Medicine Advisor1.4yrssin datossin datos
Noriyuki Kasahara
Chief Scientific Advisor & Member of Scientific Advisory Boardno dataUS$488.91ksin datos
Alan Cohen
Senior VP & Therapeutic Area Head of Pulmonologyno datasin datossin datos
Christopher Simms
Chief Commercial & Business Officer1.8yrssin datossin datos
1.6yrs
Permanencia media
63yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de FDMT no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
John Milligan
Executive Chairman5.8yrsUS$255.00k0.19%
$ 923.0k
David Kirn
Co-Founder12.8yrsUS$2.05m3.17%
$ 15.3m
Noriyuki Kasahara
Chief Scientific Advisor & Member of Scientific Advisory Boardless than a yearUS$488.91ksin datos
Charles Theuer
Independent Director10.5yrsUS$135.00k0.080%
$ 384.8k
Susannah Gray
Independent Director5.9yrsUS$135.00k0%
$ 0
Paul Utz
Member of Scientific Advisory Board2.5yrssin datossin datos
Richard Moss
Member of Scientific Advisory Board2.5yrssin datossin datos
Jacob Chacko
Independent Director7.3yrsUS$135.00k0%
$ 0
Shawn Tomasello
Independent Director5.6yrsUS$132.50k0%
$ 0
Amit Gaggar
Member of Scientific Advisory Board2.5yrssin datossin datos
Nancy Miller-Rich
Independent Director5.6yrsUS$122.50k0%
$ 0
Arshad Khanani
Chair of Retina Advisory Board1.8yrssin datossin datos
5.6yrs
Permanencia media
63yo
Promedio de edad

Junta con experiencia: La junta directiva de FDMT se considera experimentada (5.6 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/06/10 13:44
Precio de las acciones al final del día2026/06/10 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

4D Molecular Therapeutics, Inc. está cubierta por 18 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Huidong WangBarclays
Eliana MerleBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research